🔎 Trials Near Me

መነሻ › ሉኬሚያ › Pennsylvania

በPennsylvania ለሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለሉኬሚያ የሚደረጉ 15 ጥናቶች በPennsylvania ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በPennsylvania ውስጥ ያሉ ከተሞች

Official study text (English)

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
30 Days · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Spoknwrd Clinical Trials Inc., Easton
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT06824168

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Pittsburgh
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 18 · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07509151

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT07586618

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Pennsylvania, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ7 እስከ 25 · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT05082519

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 60 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT03680677

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ0 እስከ 29 · ሁሉም ጾታዎች · የተሻሻለው በ7 ጁላይ 2026 · NCT07464951

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site 2, Pittsburgh
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Saint Christopher's Hospital for Children, Philadelphia
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሜይ 2026 · NCT01790152

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
1 Month – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ15 ኤፕሪ 2026 · NCT06839456

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Hospital of the University of Pennsylvania, Philadelphia
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

  • Children's Hospital of Philadelphia, Philadelphia
ተሳታዮችን በመፈለግ ላይየመጀመሪያ ደረጃ 1
እስከ እድሜ 30 · ሁሉም ጾታዎች · የተሻሻለው በ20 ፌብሩ 2026 · NCT02356653

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Philadelphia
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።